Investigational Avenues in Uncommon EGFR Mutations: NSCLC Treatment Insight
December 27th 2023Experts share treatment experiences with osimertinib and afatinib, the potential role of immunotherapy, and ongoing investigations with ADCs and emerging TKIs for patients with uncommon EGFR mutations.
Read More
UNICORN Study: Osimertinib and Other Emerging Treatments for Uncommon EGFR Mutations
December 27th 2023Insights into how the UNICORN study, which assessed osimertinib, is impacting treatment decisions for uncommon EGFR mutations, and other ongoing trials shedding light on effective treatments for this patient population.
Read More
Navigating Post-Afatinib Progression: Treatment Sequencing Strategies in NSCLC
December 20th 2023Expert insights on sequencing treatment options for patients with uncommon EGFR mutations who have progressed on afatinib, emphasizing clinical trial considerations, biomarker testing, and emerging therapeutic approaches.
Read More
Dr. Seetharamu on Immunotherapy Treatment for Head and Neck Cancers
May 27th 2014Nagashree Seetharamu, MD, assistant professor, Medicine (Hematology and Medical Oncology), Perlmutter Cancer Center at NYU Langone, discusses the possibility of using immunotherapy agents to treat head and neck cancers.
Read More